Grail(NASDAQ) GRAL

GRAIL, Inc. helps doctors find cancer through a blood test. Its main product helps people find many cancers early. This technology makes screening easier for adults over 50.

Testing Blood to Find Cancer

• Galleri: Multi-cancer early detection test that screens for a signal shared by many cancers from a single blood draw.
• Diagnostic Aid: Medical tool designed to help find answers faster for patients who might already have cancer symptoms.
• Precision Oncology: Platform for drug companies to help with disease monitoring, risk assessment, and clinical research.
• Development Services: Support for clinical studies and therapy research provided to pharmaceutical and clinical partners.

Scaling Up and Moving Abroad

• Submitted a premarket approval application for the Galleri test to the Food and Drug Administration in Jan. 2026.
• Raised $110 million through a stock sale to Samsung C&T and Samsung Electronics in June 2026.
• Partnered with Samsung C&T to begin selling the Galleri test in South Korea and other Asian markets.
• Launched the Galleri test in the United States in mid-2021 as a laboratory developed test.
• Expanded international commercial reach through distributors in Israel, Canada, and the United Kingdom.

Building a High-Tech Laboratory

Grail maintains a laboratory in Durham, North Carolina, that can process up to one million tests every year. The system uses advanced machine learning and data science to identify cancer signals in the bloodstream.

Checking the Vital Signs

• Screening revenue was $42.6 million in the three months ended June 30, 2026, up 24% year over year.
• Net loss was $110.2 million for the three months ended June 30, 2026.
• Non-GAAP adjusted EBITDA was a loss of $90.3 million in the three months ended June 30, 2026.
• Cash and cash equivalents totaled $55.6 million as of June 30, 2026.
• Short-term marketable securities were $806.0 million as of June 30, 2026.

Bottom Line

Grail has evolved from a research-focused organization into a commercial company with a scalable testing infrastructure. Future success depends on securing regulatory approvals and broader insurance coverage for its early detection technology.